Literature DB >> 28463910

Diffusely Metastasized Adenocarcinoma Arising in a Mucinous Carcinoid of the Ovary: A Case Report.

Anne-Sophie Van Rompuy1, Adriaan Vanderstichele, Ignace Vergote, Philippe Moerman.   

Abstract

Mucinous (goblet cell) carcinoids are a rare type of ovarian carcinoid tumors. Only a limited number of primary mucinous carcinoids of the ovary have been reported in the literature. We describe the case of a 55-year-old woman with a diffusely metastasized adenocarcinoma arising in a primary ovarian mucinous carcinoid. The differential diagnosis with a metastatic goblet cell carcinoid from the appendix or elsewhere can be very challenging. In our case, especially the immunohistochemical profile of the tumor with diffuse positivity for cytokeratin 7 and PAX8, and no expression of cytokeratin 20 and CDX2, directed us toward a primary ovarian origin. Expression of PAX8 in ovarian mucinous carcinoid has never been reported before.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28463910     DOI: 10.1097/PGP.0000000000000398

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  3 in total

1.  Tumor-to-tumor metastasis from appendiceal adenocarcinoma to an ovarian mature teratoma, mimicking malignant transformation of a teratoma: a case report.

Authors:  Mitsutake Yano; Tomomi Katoh; Tetsuya Hamaguchi; Eito Kozawa; Mei Hamada; Koji Nagata; Masanori Yasuda
Journal:  Diagn Pathol       Date:  2019-08-14       Impact factor: 2.644

2.  Metastatic serous borderline tumor with micro-invasive ovarian carcinoma presenting as a breast lump: A case report.

Authors:  Fengge Dong; Xiao Xie; Xue Wei; Miao-Miao Jiao; Junwu Duan; Linlin Pan; Lirong Bi; Zhimin Fan; Ming Yang
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.889

Review 3.  Primary ovarian carcinoid: Two cases report and review of literature.

Authors:  Li-Rong Zhai; Xi-Wen Zhang; Tong Yu; Zhen-De Jiang; Dong-Wei Huang; Yan Jia; Man-Hua Cui
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.